Skip to main content
. Author manuscript; available in PMC: 2016 Feb 1.
Published in final edited form as: Breast Cancer Res Treat. 2015 Jan 28;149(3):607–618. doi: 10.1007/s10549-015-3270-1

Fig. 6.

Fig. 6

Imetelstat, trastuzumab, and combination treatment decrease primary tumor growth in vivo. A) Tumor volume of HCC1954 cells by caliper measurements in PBS control (thrice weekly, n=9), trastuzumab (20 mg/kg twice weekly, n=10), imetelstat (30 mg/kg, thrice weekly, n=10), and combination (trastuzumab twice weekly and imetelstat thrice weekly, n=9) treated NSG mice. Average ± SEM B) Rate of tumor growth calculated from A) is the slope of line of the average tumor volume over time for each treatment group